SecBot SecBot
SECBOTREPLAY Home › Report › LIVN

LIVN · LivaNova reported strong full-year 2025 results with double-digit…

LivaNova PLC · 8-K filed Feb 25, 2026 at 06:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed Feb 25, 2026 at 06:05 ET

LivaNova reported strong full-year 2025 results with double-digit revenue growth and improved margins, driven by both Cardiopulmonary and Neuromodulation segments. Despite a GAAP loss due to a $365.6 million environmental liability, adjusted earnings grew 15.4%. The company issued 2026 guidance for 6-7% revenue growth and $4.15-$4.25 adjusted EPS, supported by increased Medicare reimbursement and FDA approval for a new digital health platform.

  • Full-year 2025 revenue grew 10.7% to $1.39 billion, with Cardiopulmonary up 14.9% and Neuromodulation up 7.0%
  • Full-year adjusted EPS was $3.90, up 15.4% from $3.38 in 2024
  • GAAP loss of $4.45 per share due to $365.6 million SNIA environmental liability expense
  • 2026 guidance: 6-7% constant-currency revenue growth and $4.15-$4.25 adjusted EPS

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access